Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOLA trial of cabozantinib plus lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors
2024-516612-16-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib and lanreotide in apudoma (NET), Gastroenteropancreatic Carcinoid Tumor and thoracic neuroendocrine tumor, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Safety and tolerability. Planned start Nov 2024; status: authorised.
02
Drugs
cabozantiniblanreotide
03
Conditions
apudoma (NET)Gastroenteropancreatic Carcinoid Tumorthoracic neuroendocrine tumor
Beyond the preview
Go deeper on 2024-516612-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516612-16-00.